ChiCTR2400087356 版本V1.1 版本创建时间2025/02/27 15:39:04 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400087356 

最近更新日期:

Date of Last Refreshed on:

2024-07-25 15:46:10 

注册时间:

Date of Registration:

2024-07-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

自拟“慈虎消痛汤”治疗痛风性关节炎急性期湿热毒瘀证临床疗效的观察性研究

Public title:

Observational study on the clinical efficacy of self formulated "Cihu Xiaotong decoction" in the treatment of acute stage of gouty arthritis with dampness heat toxin stasis syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

自拟“慈虎消痛汤”治疗痛风性关节炎急性期湿热毒瘀证临床疗效的观察性研究

Scientific title:

Observational study on the clinical efficacy of self formulated "Cihu Xiaotong decoction" in the treatment of acute stage of gouty arthritis with dampness heat toxin stasis syndrome

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李鑒江 

研究负责人:

陈恩生 

Applicant:

Li Jianjiang 

Study leader:

Chen Ensheng  

申请注册联系人电话:

Applicant telephone:

+86 139 0223 0247

研究负责人电话:

Study leader's
telephone:

+86 138 2446 9891

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

13902230247@163.com

研究负责人电子邮件:

Study leader's E-mail:

chenensheng1@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市海珠区江海街道石榴岗路13号

研究负责人通讯地址:

广东省广州市海珠区江海街道石榴岗路13号

Applicant address:

No.13,Shiliugang Road,Haizhu Guangzhou,Guangdong

Study leader's address:

No.13,Shiliugang Road,Haizhu Guangzhou,Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南方医科大学中西医结合医院

Applicant's institution:

Southern Medical University Hospital of Integrater Traditional Chinese and Western Medicine

研究负责人所在单位:

南方医科大学中西医结合医院

Affiliation of the Leader:

Southern Medical University Hospital of Integrater Traditional Chinese and Western Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024008-2024-06-K1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医科大学中西医结合医院医学伦理委员会

Name of the ethic committee:

Southern Medical University Hospital of Integrater Traditional Chinese and Western Medicine ethics committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-25 00:00:00

伦理委员会联系人:

李爱荣

Contact Name of the ethic committee:

Li Airong

伦理委员会联系地址:

广东省广州市海珠区江海街道石榴岗路13号

Contact Address of the ethic committee:

No.13,Shiliugang Road,Haizhu Guangzhou,Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 6165 0040

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学中西医结合医院

Primary sponsor:

Southern Medical University Hospital of Integrater Traditional Chinese and Western Medicine

研究实施负责(组长)单位地址:

广东省广州市海珠区江海街道石榴岗路13号

Primary sponsor's address:

No.13,Shiliugang Road,Haizhu Guangzhou,Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong Province

City:

单位(医院):

南方医科大学中西医结合医院

具体地址:

广东省广州市海珠区江海街道石榴岗路13号

Institution
hospital:

Southern Medical University Hospital of Integrater Traditional Chinese and Western Medicine

Address:

No.13,Shiliugang Road,Haizhu Guangzhou,Guangdong

经费或物资来源:

Source(s) of funding:

none

研究疾病:

痛风性关节炎  

Target disease:

gout

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究旨在为痛风性关节炎急性期的治疗提供一种可行有效的治疗方案,通过临床观察,研究慈虎消痛汤对治疗痛风性关节炎急性期临床疗效。  

Objectives of Study:

The aim of this study is to provide a feasible and effective treatment plan for the acute phase of gouty arthritis. Through clinical observation, the clinical efficacy of Cihu Xiaotong Tang in treating the acute phase of gouty arthritis is studied.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)患者自愿参与研究,并签署知情同意书; (2)年龄18 周岁至70周岁成年人,性别不限; (3)同时符合中、西医诊断标准且坚持服用方剂,辨证分型及方药记录完整者; (4)本次痛风发作时间不超过48 小时。

Inclusion criteria

(1),;Patients voluntarily participated in the study and signed the informed consent form; (2)Adults aged 18 to 70 years old, regardless of gender; (3)Those who meet both traditional Chinese and Western medicine diagnostic standards and insist on taking prescriptions, with complete syndrome differentiation and prescription records; (4)This gout attack lasted no more than 48 hours.

排除标准:

(1)属于慢性痛风性关节炎患者或正处于痛风发作间歇期; (2)四诊资料收集不全者; (3)合并其他风湿免疫疾病者,如系统性红斑狼疮、强直性脊柱炎、干燥综合征、银屑病关节炎等; (4)合并其他系统严重疾病者,如严重心脑血管损伤,肝、肾功能损伤等; (5)药物过敏者; (6)精神疾病患者及无法配合患者; (7)妊娠妇女或哺乳期妇女。

Exclusion criteria:

(1)Patients with chronic gouty arthritis or in the intermittent period of gout attacks; (2)Those with incomplete collection of data; (3)Those combined with other rheumatic and immune diseases, such as systemic lupus erythematosus, ankylosing spondylitis, Sjogren's syndrome, psoriatic arthritis, etc.; (4)Those combined with other serious systemic diseases, such as severe cardiovascular and cerebrovascular injuries, liver and kidney function impairment, etc.; (5)People with drug allergies; (6)Mentally ill patients and patients who are unable to cooperate; (7)Pregnant or breastfeeding women.

研究实施时间:

Study execute time:

From 2024-07-24 00:00:00 To 2025-07-23 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-08-01 00:00:00 To 2025-02-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

23

Group:

control group

Sample size:

干预措施:

基础治疗

干预措施代码:

Intervention:

Basic treatment

Intervention code:

组别:

观察组

样本量:

23

Group:

observation group

Sample size:

干预措施:

基础治疗+慈虎消痛汤

干预措施代码:

Intervention:

Basic treatment + Cihu Xiaotong decoction

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

广州市 

Country:

China

Province:

Guangdong

City:

单位(医院):

南方医科大学中西医结合医院 

单位级别:

三甲 

Institution
hospital:

No.13,Shiliugang Road,Haizhu Guangzhou,Guangdong

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

VAS疼痛评分

指标类型:

主要指标

Outcome:

visual analogue scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血尿酸

指标类型:

主要指标

Outcome:

blood uric acid

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Blood routine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

次要指标

Outcome:

liver function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

次要指标

Outcome:

renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症候积分

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine Syndrome Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血沉

指标类型:

次要指标

Outcome:

ESR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

CRP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

关节彩超

指标类型:

次要指标

Outcome:

joint colour ultrasound

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

血液

Sample Name:

blood

Tissue:

blood

人体标本去向

使用后销毁  

说明

使用后销毁

Fate of sample:

Destruction after use  

Note:

destruction after use

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用Excel记录和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Record and manage by Excel

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-07-25 15:45:53